Loading…

Cost Per Response Analysis of Nivolumab Versus Everolimus in the Treatment of Patients Previously Treated with Advanced Renal Cell Carcinoma – Brazil Private Health Care System Perspective

OBJECTIVES: Nivolumab demonstrated a significant survival benefit when compared with everolimus (median OS 25.0 vs 19.6 months; hazard ratio: 0.73, P=0.002) in a randomized Phase III trial conducted in patients with advanced renal cell carcinoma (aRCC) who had received previous anti-angiogenic treat...

Full description

Saved in:
Bibliographic Details
Published in:Value in health 2017-10, Vol.20 (9), p.A875
Main Authors: Brust, L, Bernardino, G, Aratangy, G, Tanaka, S, Paladini, L, Borges, L, Clark, OA
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVES: Nivolumab demonstrated a significant survival benefit when compared with everolimus (median OS 25.0 vs 19.6 months; hazard ratio: 0.73, P=0.002) in a randomized Phase III trial conducted in patients with advanced renal cell carcinoma (aRCC) who had received previous anti-angiogenic treatment. Similarly, a substantially higher objective response rates favouring patients receiving nivolumab (25.1% vs 5.4%; odds ratio: 5.98, p
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2017.08.2579